Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 701 to 725 of 921

TitleReference numberPublishedLast updated
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanomaTA414
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitorTA415
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA406
Secukinumab for treating active ankylosing spondylitisTA407
Pegaspargase for treating acute lymphoblastic leukaemiaTA408
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusionTA409
Talimogene laherparepvec for treating unresectable metastatic melanomaTA410
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastasesTA412
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelTA391
Bosutinib for previously treated chronic myeloid leukaemiaTA401
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancerTA403
Degarelix for treating advanced hormone-dependent prostate cancerTA404
Trifluridine–tipiracil for previously treated metastatic colorectal cancerTA405
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenTA259
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blastsTA399
Nivolumab in combination with ipilimumab for treating advanced melanomaTA400
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA387
Adalimumab for treating moderate to severe hidradenitis suppurativaTA392
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA393
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA394
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancerTA395
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanomaTA396
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetesTA390

Results per page

  1. 10
  2. 25
  3. 50
  4. All